Zevorcabtagene Autoleucel Injection
Conditions
Interventions
group of patients treated with zevorcabtagene autoleucel:None
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients who received infusion of zevorcabtagene autoleucel after its marketing approval. 2. Aged >= 18, <= 85 years. 3. Complete clinical medical records with available baseline data, treatment information, efficacy evaluation, safety data and follow up information. 4. Accessible follow up data for the assessment of survival, efficacy and safety outcomes.
Exclusion criteria
Exclusion criteria: 1.Patients with incomplete medical records and missing key baseline, efficacy, safety or follow-up data that prevent assessment of primary endpoints. 2.Patients who did not complete at least one efficacy and safety evaluation after zevorcabtagene autoleucel infusion. 3.Patients complicated with other malignant tumors with expected survival less than 3 months. 4.Patients with duplicate enrollment or repeated data entry. 5.Patients lost to follow up without valid survival or efficacy information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety profiles (Cytokine Release Syndrome, Immune Effect or Cell Related Neurotic Syndrome, etc.);Overall Survival;Treatment efficacy (overall response rate, complete response rate, progression-free survival); | — |
Countries
China
Contacts
Public ContactMi Jianqing
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed